Mesenchymal stem cell therapy for congenital epidermolysis bullosa

Abstract

Currently, there is no effective therapy for congenital epidermolysis bullosa (CEB), but significant advances have been made in the last decade, opening up new perspectives for treatment using cell therapy. Cell therapy today has a wide arsenal, from the use of the patient's own skin cells (keratinocyte transplantation, fibroblasts, including allogeneic ones), skin stem cells, mesenchymal stem cells (MSCs), bone marrow stem cells, Wharton's jelly, umbilical cord blood, induced pluripotent stem cells). The role of MSC exosomes in regulating and accelerating regeneration during cell therapy has been discovered. There is hope for the creation of a new class of drugs based on exosomes to accelerate the healing of skin wounds